Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older
Go back to Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older| Alabama Power Co. 5.875% Sr. Notes Series 2007B (NASDAQ: ALM) | Delayed: 13.84 -0.29 (2.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.13 | 52 Week High | $27.10 | |||
| Open | $14.32 | 52 Week Low | $24.10 | |||
| Day High | $14.59 | P/E | N/A | |||
| Day Low | $13.68 | EPS | $0.00 | |||
| Volume | 7,863,911 | |||||
| Alabama Power Co. 5.875% Sr. Notes Series 2007B (NASDAQ: ALM) | Delayed: 13.84 -0.29 (2.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.13 | 52 Week High | $27.10 | |||
| Open | $14.32 | 52 Week Low | $24.10 | |||
| Day High | $14.59 | P/E | N/A | |||
| Day Low | $13.68 | EPS | $0.00 | |||
| Volume | 7,863,911 | |||||
